In 2026, U.S. agreements lower costs of GLP-1 drugs for obesity and diabetes, impacting Medicare and Medicaid coverage with a focus on starter dose affordability and access limitations.

The Trump administration's CMS decision excludes costly obesity treatments from Medicare coverage, highlighting challenges in drug pricing and healthcare policy reforms.